Pure red cell aplasia as first manifestation of splenic marginal zone lymphoma-successful treatment with rituximab: a case report by Anastasiadis, Athanasios et al.
Case report
Open Access
Pure red cell aplasia as first manifestation of splenic marginal zone
lymphoma-successful treatment with rituximab: a case report
Athanasios Anastasiadis
1*, Dimitrios Margaritis
1, Ioannis Kotsianidis
1,
Emmanouil Spanoudakis
1, Anna Christoforidou
1, Ioannis Kostopoulos
2
and Constantinos Tsatalas
1
Addresses:
1Department of Haematology, Democritus University of Thrace Medical School, University Hospital of Alexandroupolis,
Alexandroupolis, Greece
2Department of Pathology, Aristotle University Medical School, Thessaloniki, Greece
Email: AA* - anasttha@otenet.gr; DM - dmargari@med.duth.gr; IK - jankots@hotmail.com; ES - emmanouilspanoudakis@yahoo.com;
AC - annachristof@yahoo.gr; IK - kostop@med.auth.gr; CT - ktsatala@med.duth.gr
*Corresponding author
Received: 26 March 2009 Accepted: 23 July 2009 Published: 18 August 2009
Cases Journal 2009, 2:6913 doi: 10.4076/1757-1626-2-6913
This article is available from: http://casesjournal.com/casesjournal/article/view/6913
© 2009 Anastasiadis et al.; licensee Cases Network Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0),
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Introduction: Acquired pure red cell aplasia is a rare disorder, usually appearing secondary to
various pathologic conditions such as thymoma, systemic autoimmune diseases or in the course of
lymphomas. Conventional treatment consists of immunosuppression with corticosteroids,
antithymocyte globulin or cyclosporin-A.
Case presentation: 8 weekly courses of rituximab were administered to a patient who presented
with pure red cell aplasia secondary to newly diagnosed splenic marginal zone lymphoma. Transfusion
independence was achieved after the 6
th course, and pure red cell aplasia receded completely with
therapy.
Conclusion: Pure red cell aplasia may ensue early in the course of splenic marginal zone lymphoma
and other low grade lymphomas. Rituximab is a safe and effective alternative treatment for pure red
cell aplasia secondary to lymphoproliferative disorders.
Introduction
Acquired pure red cell aplasia (PRCA) is characterized by
normochromic normocytic anemia, reticulocytopenia
and a marked reduction of bone marrow erythroblasts
(<5%), without any defects in the white blood cell and
megakaryocytic lineages [1-5]. Most cases are secondary to
various systemic disorders, lymphomas comprising a
major, yet heterogeneous group of primary causes. There
are currently no specific treatment guidelines for PRCA,
though proposals have been made.
Case presentation
A 67-year-old Greek man was referred to our department
because of leucopenia, marked anemia and splenomegaly.
Progressively worsening anemia-related symptoms had
started 8 weeks prior to admission. The patient also
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Physical examination revealed pallor and moderate
splenomegaly (5 cm below the left costal margin). The
liver and lymph nodes were not palpable. The rest of the
physical examination was normal.
Blood tests showed profound anemia and moderate
neutropenia (Hct: 19.5%, MCV: 80fl, WBC: 2730/mm
3,
PMN: 1460/mm
3, PLT: 249000/mm
3). Serum ferritin was
normal and reticulocyte count was 0.23%. Other abnor-
mal tests included an elevated fasting serum glucose level
(219 mg/dl), a prolonged partial thromboplastine time
of 68.1 sec (norm. 26-35 sec) that was not corrected after
1:1 dilution with normal plasma, and an extremely high
erythropoetin level of 409.4 U/ml (norm. 4-24 U/ml).
Subsequent clotting factor assays showed the existence of
a lupus anticoagulant. Serum electrophoresis and immu-
nofixation did not reveal existence of a monoclonal
paraprotein. Serology was negative for autoimmune
disorders and viral infections (HBV, HCV, HIV and
CMV). CT scan did not reveal any lymphadenopathy in
the thorax, abdomen and pelvis, whereas CT and MRI of
the upper abdomen showed diffuse splenomegaly without
any focal lesions in the splenic parenchyma (Figure 1).
A bone marrow aspirate and trephine biopsy were further
obtained, revealing increased cellularity and a marked
reduction and maturation arrest of the erythroid lineage in
the proerythroblast stage. A lymphocyte infiltrate was also
found, consisting of small, mature lymphocytes without
villi (Figure 2A) and with paratrabecular, pericapillary and
intrasinusoidal distribution in the marrow. Erythroid
lineage comprised 4% and lymphocytes 60% of total
bone marrow cells. Lymphocytes were CD20+, CD19+,
CD22+, CD5-,C D 1 0 -, CD103-,C D 2 3 -,s I g M +b y
immunohistochemistry and flow cytometry. No periph-
eral blood involvement was detected by flow cytometry.
Additional serum testing for Parvovirus B19 was negative.
Initial diagnosis was pure red cell aplasia secondary to
low-grade non-Hodgkin’s lymphoma.
The patient was treated with 8 weekly courses of rituximab
at a dose of 375 mg/kg. Reticulocyte count rose to 5.3%
after the 5
th cycle and he achieved transfusion indepen-
dence after the 6
th cycle of treatment, having been
transfused with a total number of 13 units of packed red
cells since the day of admission. He was subsequently
subjected to splenectomy. Biopsy of the spleen confirmed
the diagnosis of splenic marginal zone lymphoma
(SMZL). He remains alive and well since then, having
achieved both complete remission of his PRCA (Figure 2B
and 2C) and a very good partial remission of his
SMZL, with a median hematocrit of 43% and a marrow
infiltrate of less than 5% at subsequent marrow testing
(Figure 2C).
Discussion
PRCA is a rare disorder, defined as normochromic
normocytic anemia, reticulocytopenia of <1% and marked
reduction (<5%) or absence of erythroblasts in the bone
marrow, without any abnormalities in the white blood cell
and megakaryocytic lineages [1-5]. It is seldom idiopathic,
the usual underlying cause being any of a variety of
systemic disorders. The list includes thymoma, collagen
vascular diseases, lymphoproliferative disorders, solid
tumors, infections, severe renal failure, medications,
pregnancy, severe nutritional deficiencies and other, rarer
causes [1-5]. Possible pathogenetic mechanisms for its
development include anti-erythropoetin antibody forma-
tion, T-cell mediated disruption of erythroblast matura-
tion or NK-cell mediated cytotoxicity against the
erythroblasts [3,5,6]. B-chronic lymphocytic leukemia
(B-CLL) is the commonest of lymphomas associated
with PRCA in its course (1-6% of all cases of B-CLL).
T-cell large granular lymphocytic leukemia (T-LGL) is
Figure 1. Axial (A) and coronal (B) view of the patient’s
abdominal MRI. Splenomegaly is evident. Spleen size was
calculated 18 cm × 15 cm × 11 cm. No focal lesions or hilar
lymphadenopathy were detected.
Figure 2. Bone marrow aspirates at various stages of
treatment. (A) At diagnosis only sporadic proerythroblasts
are visible. Aspirate consists mainly of the lymphoid infiltrate
and a few neutrophils, plasma cells and mast cells. (B) After
completion of treatment with rituximab erythroid series has
recovered, a left shift evident. Lymphoid cells are still
abundant. (C) One year after splenectomy erythroblasts in all
maturation stages prevail. Lymphoid cells are sparse (<5%,
confirmed by trephine biopsy).
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immune dysregulation, autoimmune phenomena being
their major features.
Splenic marginal zone lymphoma is an uncommon
lymphoproliferative disorder, comprising 1% of all
lymphoid neoplasms. The malignant cell immunopheno-
type is not distinctive and sometimes diagnosis is one
of exclusion [6]. It usually presents with splenomegaly,
lymphadenopathy limited to the splenic hilum and bone
marrow infiltration. The liver and peripheral blood may
be involved [6]. In one-third of cases a monoclonal IgM
paraprotein is detectable and autoimmune phenomena
like autoimmune hemolytic anemia, lupus anticoagulant
and other acquired inhibitors to clotting factors have been
described [6]. PRCA secondary to SMZL has been reported
in the literature in only two cases so far [7,8], only one of
whom was treated with rituximab [7]. SMZL is treated by
splenectomy, a procedure aiding not only in debulking
disease burden but also in reducing marrow infiltration.
Recent reports have demonstrated the effectiveness of
rituximab in patients for whom splenectomy is considered
hazardous [9-11].
T r e a t m e n to fP R C Ac o n s i s t so fv a r i o u st y p e so fi m m u n o -
suppressive drugs, the most popular of which is cortico-
steroids. Other regimens include cyclosporine-A,
antithymocyte globulin and azathioprine [12]. However,
sporadic reports on the use of rituximab for PRCA secondary
to B-cell lymphoid neoplasms, mainly B-CLL [13,14], are
slowly emerging, adding a promising alternative to the
current armamentarium. Although studies with more than
four patients are lacking due to the rarity of the disorder, all
reports up to date have shown excellent results.
In our patient’s case, corticosteroids were avoided because
of his newly diagnosed diabetes mellitus. Decision for
rituximab administration was taken on the basis of its
efficacy against both PRCA and SMZL. Although treatment
resulted in remission of PRCA and a substantial reduction
of marrow infiltration by the SMZL, splenectomy was
finally decided because of the persistence of splenomegaly
six months after discontinuation of treatment with
rituximab.
Conclusion
Although rare, PRCA must be considered as a possible
cause of severe anemia in patients with lymphoprolifera-
tive disorders, even at diagnosis. For such cases rituximab
appears to be a safe and effective treatment alternative to
other immunosuppressive drugs.
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